Tag Archives: PDL1

I/O: The Strategic Supernova In Cancer Today
June 22, 2016

With the big cancer confab ASCO 2016 fading into memory, R&D teams everywhere are getting back to work on their cancer programs – and across the industry many of them will be doing the same work, on the same targets,

3 Comments